RT Journal Article SR Electronic T1 Dual antiplatelet therapy after percutaneous coronary intervention: Personalize the duration JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP 325 OP 332 DO 10.3949/ccjm.88a.20113 VO 88 IS 6 A1 Travis M. Howard A1 Umesh N. Khot YR 2021 UL http://www.ccjm.org/content/88/6/325.abstract AB The recommended duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with a drug-eluting stent has changed from 1 year for all to a more personalized approach based on the patient’s risks of ischemia and bleeding. The trend is toward shorter treatment in view of lower rates of late and very late stent thrombosis with newer drug-eluting stents and the risk of bleeding with DAPT. But some patients at high risk of ischemic events and low risk of bleeding may benefit from longer treatment.